A HIGH ANTI-INFLAMMATORY RESPONSE IS ASSOCIATED WITH INTERMEDIATE-TERM MORTALITY IN PATIENTS WITH SEPSIS

CLINICAL OUTCOME OF SEPTIC PATIENTS WITH UNDETECTABLE VITAMIN D LEVELS AT ICU ADMISSION

BIOMARKERS MESUARED WITHIN 24 HOURS FROM THE ONSET OF SEPTIC SHOCK AND 28-DAY MORTALITY

HEALTH-CARE ASSOCIATED INFECTIONS. PATIENT CHARACTERISTICS AND INFLUENCE ON THE CLINICAL OUTCOME OF PATIENTS ADMITTED TO ICU. ENVIN-HELICS REGISTRY DATA

CHRONICALLY CRITICALLY ILL PATIENTS: DIFFERENT BEHAVIOR IN SEVERE SEPSIS AND SEPTIC SHOCK?

OUTCOMES IN PATIENTS WITH SEVERE SEPSIS OR SEPTIC SHOCK WITH A URINARY SOURCE OF INFECTION IN THE ICU

TIME COURSE AND CLINICAL RELEVANCE OF THROMBOCYTOPENIA IN CRITICAL ILLNESS

LONG-TERM OUTCOMES OF ADULT PATIENTS ADMITTED WITH SEPSIS TO BRAZILIAN PUBLIC HOSPITALS: A NATIONAL RETROSPECTIVE MATCHED COHORT STUDY

OUTCOMES OF SEPTIC SHOCK DUE TO MULTIDRUG RESISTANT BACTERAEMIA TREATED WITH PHOSPHOMYCINE

90-DAY MORTALITY OF SEVERE SEPSIS AND SEPTIC SHOCK IS REDUCED BY INITIATION OF ORAL BETA-BLOCKER THERAPY AND INCREASED BY DISCONTINUATION OF A PRE-EXISTING BETA-BLOCKER TREATMENT